Bernard Zinman

Q: What Schools Are Affiliated With Bernard Zinman

Bernard Zinman is affiliated with the following schools: University of Western Ontario, George Washington University, University of Manitoba, University of Toronto, Osaka University

Bernard Zinman's AcademicInfluence.com Rankings

Bernard Zinman

Philosophy

#2970

World Rank

#4910

Historical Rank

Logic

#900

World Rank

#1466

Historical Rank

philosophy Degrees

Bernard Zinman

Biology

#3412

World Rank

#5225

Historical Rank

Endocrinology

#15

World Rank

#18

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Bernard Zinman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bernard Zinman is a Canadian clinical and research endocrinologist, whose research at the University of Toronto focuses on type 1 and type 2 diabetes. He directed the Mount Sinai Hospital Leadership Sinai Centre for Diabetes and the Banting and Best Diabetes Centre . In 2019, he was appointed as an Officer to the Order of Canada in recognition of his scientific contributions, including the development of preventative therapies for diabetes.

(See a Problem?)

Bernard Zinman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (2015) (4686)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. (2005) (4036)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (2006) (2910)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. (2019) (2717)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) (2621)
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes (2009) (2534)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) (2459)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (2348)
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. (2001) (1938)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006) (1681)
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (2017) (1265)
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy (2006) (997)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (2016) (822)
Are Metabolically Healthy Overweight and Obesity Benign Conditions? (2013) (808)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) (2009) (807)
Impaired Fasting Glucose and Impaired Glucose Tolerance (2007) (769)
Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. (2003) (764)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial (2019) (749)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008) (744)
The prevention or delay of type 2 diabetes. (2002) (727)
Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). (2009) (594)
Ramipril and the development of diabetes. (2001) (572)
Renal and retinal effects of enalapril and losartan in type 1 diabetes. (2009) (557)
Rosiglitazone-Associated Fractures in Type 2 Diabetes (2008) (509)
Liraglutide and Renal Outcomes in Type 2 Diabetes (2017) (495)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017) (492)
Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. (2000) (474)
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes (2007) (466)
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. (2011) (465)
Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited (2008) (460)
1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. (1998) (445)
Risk of development of diabetes mellitus after diagnosis of gestational diabetes (2008) (438)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (2017) (424)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. (2017) (415)
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. (2004) (396)
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. (2014) (393)
Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? (2005) (389)
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2008) (385)
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. (2002) (365)
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. (2015) (362)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. (2019) (359)
Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. (2000) (356)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials (2015) (355)
Insulins today and beyond (2001) (349)
Simple screening tests for peripheral neuropathy in the diabetes clinic. (2000) (346)
Alternative routes of insulin delivery (2003) (340)
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis (2014) (330)
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials (2012) (323)
Changes in diabetes self-care behaviors make a difference in glycemic control: the Diabetes Stages of Change (DiSC) study. (2003) (323)
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes (2012) (321)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2018) (318)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum (2017) (314)
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. (2011) (311)
5. Prevention or Delay of Type 2 Diabetes (2016) (311)
Physical activity/exercise and diabetes mellitus. (2003) (306)
Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy (2009) (306)
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) (2010) (301)
Hyperbolic Relationship Between Insulin Secretion and Sensitivity on Oral Glucose Tolerance Test (2008) (297)
Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes (2010) (295)
The Prevalence of NIDDM and Associated Risk Factors in Native Canadians (1997) (285)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. (2017) (272)
Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. (1999) (264)
Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study (2010) (263)
Insulin Lispro in CSII: Results of a Double-Blind Crossover Study (1997) (261)
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2006) (258)
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. (2002) (249)
Specific patterns of food consumption and preparation are associated with diabetes and obesity in a Native Canadian community. (1998) (248)
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions (2013) (247)
C-reactive protein and gestational diabetes: the central role of maternal obesity. (2003) (237)
Glucose Intolerance in Pregnancy and Future Risk of Pre-Diabetes or Diabetes (2008) (235)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) (2015) (215)
Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial (2014) (215)
Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic (2001) (215)
Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study (2010) (204)
Exercise in Individuals With IDDM (1994) (204)
Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT (2011) (202)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial (2018) (201)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019) (200)
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. (2013) (200)
Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. (2004) (199)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups (2019) (191)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) (2014) (190)
Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the (2014) (190)
New guidelines for the management of diabetes: a physician's guide. Steering Committee for the Revision of the Clinical Practice Guidelines for the Management of Diabetes in Canada. (1998) (189)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials (2018) (189)
Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes (2006) (187)
The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Stu (2013) (186)
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2018) (182)
Stages of change for healthy eating in diabetes: relation to demographic, eating-related, health care utilization, and psychosocial factors. (2003) (181)
Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. (2013) (181)
A pilot school-based healthy eating and physical activity intervention improves diet, food knowledge, and self-efficacy for native Canadian children. (2005) (180)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics (2017) (180)
Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. (2004) (177)
Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. (2010) (174)
Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes (2005) (173)
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. (2010) (172)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. (2019) (172)
The impact of diabetes on survival following breast cancer (2008) (170)
Glucoregulation during moderate exercise in insulin treated diabetics. (1977) (170)
The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. (1999) (166)
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study (2000) (165)
Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. (2004) (164)
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial (2016) (162)
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. (2000) (157)
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. (1996) (155)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. (2019) (155)
Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications (2005) (152)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON) (2014) (152)
Glucoregulatory and metabolic response to exercise in obese noninsulin-dependent diabetes. (1981) (151)
Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal (2005) (149)
Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis (2013) (140)
Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association (2014) (139)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial (2017) (139)
Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. (2001) (137)
Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. (2003) (137)
The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. (2005) (135)
Effect of insulin and lipolytic agents on rat adipocyte low Km cyclic adenosine 3':5'-monophosphate phosphodiesterase. (1974) (134)
Common and rare ABCA1 variants affecting plasma HDL cholesterol. (2000) (132)
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes (2014) (131)
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial (2011) (129)
Type 2 diabetes and impaired glucose tolerance in aboriginal populations: a global perspective. (2007) (129)
Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial (2017) (129)
Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. (2019) (128)
Hepatic Glucose Production Is Regulated Both by Direct Hepatic and Extrahepatic Effects of Insulin in Humans (1996) (126)
Comparison of the Acute and Long-Term Effects of Exercise on Glucose Control in Type I Diabetes (1984) (126)
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. (2018) (125)
Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) (2017) (125)
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study (2010) (125)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial (2019) (123)
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme (2012) (122)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. (2017) (121)
Factors determining glucose tolerance in patients with thalassemia major. (1993) (121)
Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. (2014) (120)
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial (2018) (119)
Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. (2011) (118)
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality (2017) (116)
HNF-1α G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community (2002) (114)
Prospective Associations of Vitamin D With β-Cell Function and Glycemia (2011) (114)
Type 1 diabetes, hyperglycaemia, and the heart (2008) (113)
Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2017) (113)
Genetic variation of intestinal fatty acid-binding protein associated with variation in body mass in aboriginal Canadians. (1996) (111)
Fetal Sex and Maternal Risk of Gestational Diabetes Mellitus: The Impact of Having a Boy (2015) (111)
Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. (1999) (111)
Effect of maternal weight, adipokines, glucose intolerance and lipids on infant birth weight among women without gestational diabetes mellitus (2012) (110)
Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. (2006) (109)
Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort (2015) (109)
Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. (2005) (107)
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk (2017) (107)
Increasing rates of ischemic heart disease in the native population of Ontario, Canada. (2000) (106)
Nontraditional cardiovascular risk factors in pediatric metabolic syndrome. (2006) (106)
Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. (2005) (104)
Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus ( LEAD-4 Met + TZD ) (2009) (103)
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. (2018) (102)
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme (2013) (102)
Diabetes mellitus and breast cancer: a retrospective population-based cohort study (2006) (102)
Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial (2014) (101)
Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. (2004) (100)
Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta cell dysfunction and fasting glycaemia (2010) (100)
Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor γ Associated With Carotid Atherosclerosis (2004) (100)
Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. (1997) (100)
Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample (2008) (99)
Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. (1996) (97)
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2007) (95)
β-Cell Function Declines Within the First Year Postpartum in Women With Recent Glucose Intolerance in Pregnancy (2010) (93)
Physical activity, physical fitness, and insulin and glucose concentrations in an isolated Native Canadian population experiencing rapid lifestyle change. (2001) (93)
Effects of weight loss in massive obesity on insulin and C-peptide dynamics: sequential changes in insulin production, clearance, and sensitivity. (1987) (92)
Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy (2010) (92)
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial (2013) (92)
The Physiologic Replacement of Insulin (1989) (91)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. (2019) (86)
Each Degree of Glucose Intolerance in Pregnancy Predicts Distinct Trajectories of β-Cell Function, Insulin Sensitivity, and Glycemia in the First 3 Years Postpartum (2014) (86)
Body image concepts differ by age and sex in an Ojibway-Cree community in Canada. (1996) (86)
Lifestyle Variables, Non‐traditional Cardiovascular Risk Factors, and the Metabolic Syndrome in an Aboriginal Canadian Population (2006) (86)
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. (2016) (85)
Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. (2005) (85)
Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. (2016) (84)
Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. (1997) (84)
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. (2020) (83)
Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada (2006) (83)
Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes (2009) (83)
Isolated Hyperglycemia at 1 Hour on Oral Glucose Tolerance Test in Pregnancy Resembles Gestational Diabetes Mellitus in Predicting Postpartum Metabolic Dysfunction (2008) (82)
Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. (1999) (81)
Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study (2016) (81)
The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. (2002) (81)
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree. (2002) (81)
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial (2018) (81)
Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. (2009) (80)
Ethnicity modifies the effect of obesity on insulin resistance in pregnancy: a comparison of Asian, South Asian, and Caucasian women. (2006) (78)
Increased prevalence of prior breast cancer in women with newly diagnosed diabetes (2006) (77)
Novel Diabetes Drugs and the Cardiovascular Specialist. (2017) (77)
G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. (1998) (77)
Effect of macronutrient intake during the second trimester on glucose metabolism later in pregnancy. (2011) (76)
Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community (2009) (76)
Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. (2008) (76)
Low dietary fiber and high protein intakes associated with newly diagnosed diabetes in a remote aboriginal community. (1997) (75)
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. (2020) (74)
Decreased high‐molecular‐weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes (2007) (74)
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. (2019) (74)
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience (2018) (74)
Use of Ethnographic Methods for Applied Research on Diabetes Among the Ojibway-Cree in Northern Ontario (1996) (73)
Peroxisome Proliferator-Activated Receptor-γ2 P12A and Type 2 Diabetes in Canadian Oji-Cree (2000) (73)
The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. (2010) (72)
Normalization of Glycemia in Diabetics During Meals with Insulin and Glucagon Delivery by the Artificial Pancreas (1977) (72)
Insulin, glucagon, and amino acids during glycemic control by the artificial pancreas in diabetic man. (1980) (71)
Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree (2003) (71)
A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. (2001) (71)
Regression of pituitary tumors, a possible effect of bromergocryptine. (1979) (71)
Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. (1997) (71)
Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? (2011) (70)
Renal outcomes in patients with type 1 diabetes and macroalbuminuria. (2014) (70)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk (2018) (69)
Associations of prenatal metabolic abnormalities with insulin and adiponectin concentrations in human milk. (2012) (69)
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus (2007) (69)
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe (2006) (69)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. (2019) (68)
Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia. (1998) (68)
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. (2011) (67)
The relationship of cardiac diastolic dysfunction to concurrent hormonal and metabolic status in type I diabetes mellitus. (1988) (67)
Absence of association of type 2 diabetes with CAPN10 and PC-1 polymorphisms in Oji-Cree. (2001) (67)
Genetic variation in LMNA modulates plasma leptin and indices of obesity in aboriginal Canadians. (2000) (67)
Cardiometabolic Implications of Postpartum Weight Changes in the First Year After Delivery (2014) (66)
Prospective association of 25(OH)D with metabolic syndrome (2014) (66)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke: Post Hoc Analysis From the LEADER Trial (2018) (66)
Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study (1996) (66)
Pre‐gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity (2009) (65)
Cigarette smoking and cardiovascular risk factors among Aboriginal Canadian youths (2005) (64)
Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379―1381 (2011) (64)
Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulin-dependent diabetic and nondiabetic individuals. (1994) (64)
Prospective Associations of Vitamin D Status With β-Cell Function, Insulin Sensitivity, and Glycemia: The Impact of Parathyroid Hormone Status (2014) (62)
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) (62)
Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers (1999) (62)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. (2020) (62)
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008) (61)
Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in β-Cell Function (2014) (61)
Comparison of Algorithms for the Closed-Loop Control of Blood Glucose Using the Artificial Beta Cell (1981) (61)
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. (2018) (61)
The metabolic response to moderate exercise in diabetic man receiving intravenous and subcutaneous insulin. (1977) (61)
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. (2020) (60)
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. (2020) (59)
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. (2010) (59)
Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis (2015) (59)
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. (2019) (58)
Circulating vitamin D metabolites and kidney disease in type 1 diabetes. (2012) (57)
Elevated C‐reactive protein in Native Canadian children: an ominous early complication of childhood obesity (2006) (57)
Effects of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique. (1986) (57)
Genes, environment and Oji-Cree type 2 diabetes. (2003) (57)
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy? (2019) (56)
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. (2015) (56)
The Role of Insulin in the Metabolic Response to Exercise in Diabetic Man (1979) (56)
ACE-I and ARBs in early diabetic nephropathy (2002) (56)
A 1-year, randomized, treat-to-target trial (BEGIN Once Long) (2012) (56)
HNF1A G319S variant, active cigarette smoking and incident type 2 diabetes in Aboriginal Canadians: a population-based epidemiological study (2011) (56)
Primary prevention of type 2 diabetes in high-risk populations. (2000) (56)
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. (2016) (56)
The metabolic response to glycemic control by the artificial pancreas in diabetic man. (1979) (55)
Sodium‐glucose co‐transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol (2019) (55)
Hormonal and metabolic responses during coronary artery bypass surgery: role of infused glucose. (1989) (55)
Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control (2005) (54)
Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function (2012) (54)
A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes (2005) (54)
The physiologic replacement of insulin. An elusive goal. (1989) (53)
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. (2019) (53)
LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes (2014) (53)
Bioelectrical impedance analysis (BIA) using bipolar foot electrodes in the assessment of body composition in Type 2 diabetes mellitus (1998) (53)
Maternal Insulin Sensitivity During Pregnancy Predicts Infant Weight Gain and Adiposity at 1 Year of Age (2010) (53)
Major gaps in diabetes clinical care among Canada's First Nations: results of the CIRCLE study. (2011) (53)
Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. (2000) (53)
Metabolic response of normal man and insulin-infused diabetics to postprandial exercise. (1982) (53)
Administrative data algorithms can describe ambulatory physician utilization. (2007) (52)
Stability of Insulin Lispro in Insulin Infusion Systems (1997) (51)
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial (2019) (51)
Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. (2004) (50)
Impaired glucose tolerance of pregnancy is a heterogeneous metabolic disorder as defined by the glycemic response to the oral glucose tolerance test. (2006) (50)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial (2016) (50)
Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. (1997) (49)
Hypoadiponectinaemia in South Asian women during pregnancy: evidence of ethnic variation in adiponectin concentration (2004) (49)
Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample (2007) (49)
Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. (2016) (49)
Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth (2007) (48)
Fetal sex and maternal risk of pre‐eclampsia/eclampsia: a systematic review and meta‐analysis (2017) (47)
Insulins: past, present, and future. (2012) (47)
White blood cell subtypes, insulin resistance and β‐cell dysfunction in high‐risk individuals – the PROMISE cohort (2014) (47)
Adiponectin in a native Canadian population experiencing rapid epidemiological transition. (2003) (47)
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial (2011) (46)
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (2017) (46)
Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) (2018) (46)
Insulin-Stimulated Glucose Transport in Circulating Mononuclear Cells From Nondiabetic and IDDM Subjects (1992) (46)
A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks (2018) (46)
Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. (2014) (45)
The impact of family history of diabetes on risk factors for gestational diabetes (2007) (45)
Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose (2009) (45)
Vitamin D and parathyroid hormone status in pregnancy: effect on insulin sensitivity, β-cell function, and gestational diabetes mellitus. (2014) (45)
The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes (2010) (45)
Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. (2013) (44)
An abnormal screening glucose challenge test in pregnancy predicts postpartum metabolic dysfunction, even when the antepartum oral glucose tolerance test is normal (2009) (44)
Serum Immunoreactive Leptin Concentrations in a Canadian Aboriginal Population With High Rates of NIDDM (1997) (44)
Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME® (2018) (44)
Maternal Serum Prolactin and Prediction of Postpartum β-Cell Function and Risk of Prediabetes/Diabetes (2016) (44)
Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population (2006) (43)
Association of parity with risk of type 2 diabetes and related metabolic disorders. (2002) (43)
Dietary intake and development of a quantitative food-frequency questionnaire for a lifestyle intervention to reduce the risk of chronic diseases in Canadian First Nations in north-western Ontario (2008) (43)
Cardiometabolic consequences of gestational dysglycemia. (2013) (43)
Relationship of the metabolic syndrome to carotid ultrasound traits (2006) (43)
Nutrient intake and food use in an Ojibwa-Cree community in Northern Ontario assessed by 24h dietary recall (1997) (42)
Changes in insulin sensitivity and clearance in anorexia nervosa. (1986) (42)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial (2013) (42)
Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes (2016) (42)
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain (2009) (42)
VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin. (1994) (41)
Glycemic Regulation Using a Programmed Insulin Delivery Device: III. Long-Term Studies on Diabetic Dogs (1979) (41)
The Effect of Postprandial Exercise on Meal-related Glucose Intolerance in Insulin-dependent Diabetic Individuals (1982) (41)
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. (2019) (41)
Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study (2009) (41)
The response to short‐term intensive insulin therapy in type 2 diabetes (2010) (41)
Risk of early progression to prediabetes or diabetes in women with recent gestational dysglycaemia but normal glucose tolerance at 3‐month postpartum (2010) (40)
The metabolic response to the euglycemic insulin clamp in type I diabetes and normal humans. (1985) (40)
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. (2021) (39)
For Insulin Infusion: A Miniature Precision Peristaltic Pump and Silicone Rubber Reservoir (1980) (38)
ROLE OF CONTINUOUS COMPONENT IN SUBCUTANEOUS "OPEN-LOOP" INSULIN DELIVERY (1980) (38)
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes (2010) (38)
Noninvasive glucose detection in human skin using wavelength modulated differential laser photothermal radiometry (2012) (38)
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial (2019) (38)
The antepartum glucose values that predict neonatal macrosomia differ from those that predict postpartum prediabetes or diabetes: implications for the diagnostic criteria for gestational diabetes. (2009) (38)
Hyperprolactinemia, hypopituitarism, and chiasmal compression due to carcinoma metastatic to the pituitary. (1981) (38)
Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. (1999) (37)
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. (2019) (37)
Free fatty acid-mediated impairment of glucose-stimulated insulin secretion in nondiabetic Oji-Cree individuals from the Sandy Lake community of Ontario, Canada: a population at very high risk for developing type 2 diabetes. (2003) (37)
Maternal pregravid weight is the primary determinant of serum leptin and its metabolic associations in pregnancy, irrespective of gestational glucose tolerance status. (2012) (36)
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. (2013) (36)
Newer insulin analogs: advances in basal insulin replacement (2013) (35)
Maternal serum adiponectin and infant birthweight: the role of adiponectin isoform distribution (2007) (35)
Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes (2013) (35)
Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections (2004) (35)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
PPARγ agonists in type 2 diabetes: how far have we come in ‘preventing the inevitable’? A review of the metabolic effects of rosiglitazone (2001) (35)
Hepatocyte nuclear factor-1 alpha G319S. A private mutation in Oji-Cree associated with type 2 diabetes. (1999) (34)
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial (2006) (34)
The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes MellitusClinical Perspective (2013) (34)
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. (2010) (34)
Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes (2005) (34)
Long-term effect of diabetes and its treatment on cognitive function (2007) (34)
Longitudinal changes in estimated and measured GFR in type 1 diabetes. (2014) (34)
Blood pressure-lowering effects of incretin-based diabetes therapies. (2014) (34)
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. (2018) (33)
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. (2020) (33)
Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. (2007) (33)
Low Serum Levels of High–Molecular Weight Adiponectin in Indo-Asian Women During Pregnancy (2006) (33)
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial (2020) (32)
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (2020) (32)
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. (2019) (32)
Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin (2010) (32)
Primary Prevention of Type 2 Diabetes: Experiences of 2 Aboriginal Communities in Canada (2003) (32)
Developing a quality of life measure for Chinese patients with diabetes. (1999) (31)
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes (2015) (31)
Multiple symmetric lipomatosis (Launois-Bensaude syndrome) - adipose tissue insensitivity to cyclic AMP. (1979) (31)
Benefits of Renin-Angiotensin Blockade on Retinopathy in Type 1 Diabetes Vary With Glycemic Control (2011) (31)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (2016) (31)
A Portable System for Continuous Intravenous Insulin Delivery: Characteristics and Results in Diabetic Patients (1980) (31)
Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials (2018) (30)
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal (2011) (30)
A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia (2015) (29)
Variation in the AU(AT)-rich element within the 3'-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. (1998) (29)
Deficiencies in the Quality of Diabetes Care (2007) (29)
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. (2019) (29)
Clinical utility of HNF1A genotyping for diabetes in aboriginal Canadians. (2000) (29)
Association between PON1 L/M55 Polymorphism and Plasma Lipoproteins in Two Canadian Aboriginal Populations (2000) (29)
Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. (2010) (29)
Genetic variation in paraoxonase‐2 is associated with variation in plasma lipoproteins in Canadian Oji‐Cree (1998) (29)
Liraglutide and the Preservation of Pancreatic Beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial (2014) (29)
Studies with an artificial endocrine pancreas. (1977) (29)
Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes (2018) (29)
The persistence of maternal vitamin D deficiency and insufficiency during pregnancy and lactation irrespective of season and supplementation (2016) (28)
Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes*s⃞ (2009) (28)
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial (2017) (28)
Association of a single nucleotide polymorphism in CPB2 encoding the thrombin‐activable fibrinolysis inhibitor (TAFI) with blood pressure (2001) (28)
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. (2014) (28)
Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes (2007) (28)
Thiazolidinediones and clinical outcomes in type 2 diabetes (2009) (28)
The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree. (2000) (28)
—6A Promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree (1998) (28)
Does Hypoadiponectinemia Explain the Increased Risk of Diabetes and Cardiovascular Disease in South Asians? A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. (2006) (27)
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis (2020) (27)
Insulinoma Resection Facilitated by the Artificial Endocrine Pancreas (1978) (27)
Cross-sectional and prospective associations between abdominal adiposity and proinsulin concentration. (2002) (27)
Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group. (1999) (27)
Utility of non‐high‐density lipoprotein cholesterol in assessing incident type 2 diabetes risk (2012) (27)
Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial (2020) (27)
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021) (26)
Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. (2019) (26)
Gestational Diabetes and Postpartum Physical Activity: Evidence of Lifestyle Change 1 Year After Delivery (2010) (26)
Metabolic response to moderate exercise in obese man during prolonged fasting. (1980) (26)
Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia (2014) (26)
Complications of Type 2 Diabetes Among Aboriginal Canadians: Increasing the Understanding of Prevalence and Risk Factors (2003) (26)
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus (2018) (25)
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial (2019) (25)
Dietary Patterns and Type 2 Diabetes Mellitus in a First Nations Community. (2016) (25)
Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. (2019) (25)
Hepatic Insulin Resistance Is an Early Determinant of Declining β-Cell Function in the First Year Postpartum After Glucose Intolerance in Pregnancy (2011) (25)
Changes Over Time in Glycemic Control, Insulin Sensitivity, and β-Cell Function in Response to Low-Dose Metformin and Thiazolidinedione Combination Therapy in Patients With Impaired Glucose Tolerance (2011) (24)
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. (2021) (24)
Circadian Variation in the Response to the Glucose Challenge Test in Pregnancy (2012) (24)
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (24)
Diabetes and exercise. (1985) (24)
Comparison of National Diabetes Data Group and American Diabetes Association diagnostic criteria for gestational diabetes in their identification of postpartum risk of glucose intolerance. (2009) (24)
Youth-onset type 2 diabetes (Y2DM) associated with HNF1A S319 in aboriginal Canadians. (1999) (24)
The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. (1989) (24)
Absence of Association Between Genetic Variation of the β3-Adrenercjic Receptor and Metabolic Pnenotypes in Oji-Cree (1998) (24)
Determinants of Insulin Resistance in Infants at Age 1 Year (2012) (23)
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. (2018) (23)
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. (2006) (23)
An evaluation of factors associated with proliferative diabetic retinopathy. (1985) (23)
Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. (2012) (23)
Counterregulatory Hormone Responses Preserved After Long-Term Intravenous Insulin Infusion Compared to Continuous Subcutaneous Insulin Infusion (1988) (22)
The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement (2021) (22)
Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. (2007) (22)
Continuous subcutaneous insulin infusion versus multiple daily injections: modeling predicted benefits in relationship to baseline A1c. (2005) (22)
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. (2018) (22)
Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes (2013) (22)
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials (2020) (22)
Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind Placebo- Controlled Trial. (2008) (22)
Diurnal metabolic and hormonal responses to mixed meals in healthy dogs. (1981) (22)
Metabolically Healthy Overweight and Obesity (2014) (21)
Triglyceride-rich lipoprotein metabolism during acute hyperinsulinemia in hypertriglyceridemic humans. (1988) (21)
Prior lactation reduces future diabetic risk through sustained postweaning effects on insulin sensitivity. (2017) (21)
A common mtDNA polymorphism associated with variation in plasma triglyceride concentration. (1997) (21)
Cross-sectional and prospective associations between proinsulin and cardiovascular disease risk factors in a population experiencing rapid cultural transition. (2001) (21)
Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers (1997) (21)
The postpartum cardiovascular risk factor profile of women with isolated hyperglycemia at 1-hour on the oral glucose tolerance test in pregnancy. (2011) (21)
Insulin Regimens and Strategies for IDDM (1993) (21)
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME (2020) (21)
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial (2019) (21)
The International Diabetes Federation World Diabetes Congress 2015 (2015) (20)
Acquired hypertrichosis lanuginosa as a sign of internal malignant disease. (1978) (20)
Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2017) (20)
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. (2020) (20)
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial (2019) (20)
Endocrine, cytogenetic and psychometric features of patients with X-isochromosome 46, X, i(Xq) Turner's syndrome: a preliminary study in nine patients. (1984) (20)
Liraglutide and Glycaemic Outcomes in the LEADER Trial (2018) (20)
Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. (1990) (20)
Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes (1997) (20)
Effect of exercise on the pancreatic polypeptide response to food in man. (1986) (19)
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: 30th Anniversary Presentations (2013) (19)
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials (2019) (19)
Disparate Associations of a Functional Promoter Polymorphism in PCK1 With Carotid Wall Ultrasound Traits (2005) (19)
Postpartum Metabolic Function in Women Delivering a Macrosomic Infant in the Absence of Gestational Diabetes Mellitus (2011) (19)
Abnormalities in the renal and vascular responses to LBNP in humans with early diabetes. (1994) (18)
Biosynthetic human insulin improves postprandial glucose excursions in type I diabetics. (1987) (18)
Exercise in diabetic man: glucose turnover and free insulin responses after glycemic normalization with intravenous insulin. (1982) (18)
Bladder cancer in the EMPA-REG OUTCOME trial (2017) (18)
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) (18)
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial (2021) (18)
The impact of insulin resistance on proinsulin secretion in pregnancy: hyperproinsulinemia is not a feature of gestational diabetes. (2005) (18)
Diabetes: Clinical inertia—a barrier to effective management of T2DM (2013) (18)
Cardiovascular disease risk profile and microvascular complications of diabetes: comparison of Indigenous cohorts with diabetes in Australia and Canada (2012) (18)
Changes Over Time in Hepatic Markers Predict Changes in Insulin Sensitivity, &bgr;-Cell Function, and Glycemia (2018) (18)
Overnight Metabolic Control with Pulsed Intermittent Versus Continuous Subcutaneous Insulin Infusion (1983) (18)
Impact of daily incremental change in environmental temperature on beta cell function and the risk of gestational diabetes in pregnant women (2018) (18)
LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial (2016) (18)
Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial (2015) (18)
The acute effects of tolbutamide on forearm metabolism. (1972) (18)
Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11) (2019) (17)
Clinical predictors and time course of the improvement in β–cell function with short‐term intensive insulin therapy in patients with Type 2 diabetes (2015) (17)
Endothelial Function in Women with and without a History of Glucose Intolerance in Pregnancy (2013) (17)
Examining the relationship between maternal body size, gestational glucose tolerance status, mode of delivery and ethnicity on human milk microbiota at three months post-partum (2020) (17)
A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide versus insulin infusion. (1994) (17)
NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. (2000) (17)
Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure. (2001) (17)
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial) (2009) (17)
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers (2022) (17)
The use of bioelectrical impedance analysis (BIA) to estimate body composition in the Diabetes Control and Complications Trial (DCCT). (1994) (17)
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial (2020) (17)
Effect of calcium on [125I]insulin binding to rat adipocytes. (1978) (17)
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. (2020) (17)
Diabetic Retinopathy and Diabetic (2003) (17)
Atrial natriuretic factor counteracts sodium-retaining actions of insulin in normal men. (1993) (16)
Effect of maternal gestational diabetes on the cardiovascular risk factor profile of infants at 1 year of age. (2013) (16)
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial (2020) (16)
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial (2021) (16)
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. (2020) (16)
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. (1996) (16)
Present and Future Expectations Regarding Insulin Infusion Systems (1981) (16)
Gender, obesity, hepatic nuclear factor-1α G319S and the age-of-onset of type 2 diabetes in Canadian Oji-Cree (2000) (16)
Open-Loop Intravenous Insulin Waveforms for Postprandial Exercise in Type I Diabetes (1983) (16)
Two‐year trial of intermittent insulin therapy vs metformin for the preservation of β‐cell function after initial short‐term intensive insulin induction in early type 2 diabetes (2018) (16)
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7) (2019) (16)
Cultural adaptation of the diabetes quality-of-life measure for Chinese patients. (1999) (16)
Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials (2018) (16)
Insulin blunts the natriuretic action of atrial natriuretic peptide in hypertension. (1994) (16)
Counterregulatory Hormone Responses After Long-Term Continuous Subcutaneous Insulin Infusion With Lispro Insulin (1998) (15)
LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes. (2007) (15)
Serum apoA1 (Apolipoprotein A-1), Insulin Resistance, and the Risk of Gestational Diabetes Mellitus in Human Pregnancy. (2019) (15)
The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. (2016) (15)
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. (2001) (15)
Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community. (2015) (15)
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial (2020) (15)
Blood glucose control and insulin clearance in unrestrained diabetic dogs portally infused with a portable insulin delivery system (1980) (15)
The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree (1999) (15)
Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. (2010) (15)
Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial (2017) (15)
Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. (2021) (15)
Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. (1999) (14)
Maternal obesity and familial history of diabetes have opposing effects on infant birth weight in women with mild glucose intolerance in pregnancy (2008) (14)
Intravenous Infusions of Sulfated Insulin Normalize Plasma Glucose Levels in Pancreatectomized Dogs (1983) (14)
APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians (2010) (14)
Similarities and differences in cardiometabolic risk factors among remote Aboriginal Australian and Canadian cohorts. (2013) (14)
Impact of Maternal Physical Activity and Infant Feeding Practices on Infant Weight Gain and Adiposity (2012) (14)
Use of vascular risk‐modifying medications for diabetic patients differs between physician specialties (2006) (14)
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial (2020) (14)
Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes (2019) (14)
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14 (2019) (14)
An insulin infusion (1981) (14)
Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. (2015) (14)
Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum (2015) (13)
Effect of Continuous Subcutaneous Insulin Infusion With Lispro on Hepatic Responsiveness to Glucagon in Type 1 Diabetes (1998) (13)
Efficacy of Feedback From Quarterly Laboratory Comparison in Maintaining Quality of a Hospital Capillary Blood Glucose Monitoring Program (1996) (13)
Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis (2020) (13)
Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. (2018) (13)
Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion (2017) (13)
Impact of maternal metabolic abnormalities in pregnancy on human milk and subsequent infant metabolic development: methodology and design (2010) (13)
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. (2020) (12)
Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus (2009) (12)
Raising diabetes awareness in the public domain (2007) (12)
Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes (2018) (12)
Electronic Flow Rate Controller for a Portable Insulin Infusion Pump (1980) (12)
Methylenetetrahydrofolate Reductase Gene, Dietary Folate, NIDDM, and Atherosclerosis in Canadian Oji-Cree (1998) (12)
Diabetes care in the U.S. and Canada. (2002) (12)
Hemochromatosis and Diabetes Mellitus (1998) (12)
Insulin pump therapy and rapid acting insulin: what have we learned? (2001) (12)
Pathophysiology of Beta Cell Failure After Prolonged Remission of Insulin-dependent Diabetes Mellitus (IDDM) (1984) (12)
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon? (2017) (12)
Insulin resistance and action in hypertriglyceridemia. (1991) (12)
Biomarkers of vascular injury and endothelial dysfunction after recent glucose intolerance in pregnancy (2018) (12)
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME (2020) (11)
Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes (2020) (11)
Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus. (1999) (11)
Absence of association between genetic variation of the beta 3-adrenergic receptor and metabolic phenotypes in Oji-Cree. (1998) (11)
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low‐dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance (2012) (11)
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial (2021) (11)
Adipokines and Incident Type 2 Diabetes in a Canadian Aborigine Population (2008) (11)
Fasting capillary glucose as a screening test for ruling out gestational diabetes mellitus. (2013) (11)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. (2016) (11)
Lower dietary vitamin E intake during the second trimester is associated with insulin resistance and hyperglycemia later in pregnancy (2013) (11)
Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes. (2016) (11)
Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort (2019) (11)
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial (2020) (11)
Adipokines and Incident Type 2 Diabetes in an Aboriginal Canadian Population: The Sandy Lake Health and Diabetes Project (2008) (11)
Hepatic fat and glucose tolerance in women with recent gestational diabetes (2018) (11)
Disparity between association and linkage analysis for HNF1A G319S in type 2 diabetes in Canadian Oji-Cree (2000) (10)
Diabetes Research and Care Through the Ages (2017) (10)
Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets (2010) (10)
The Effect of Excess Weight Gain with Intensive Diabetes Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes: Results from the Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study (2012) (10)
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study (2021) (10)
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia (2021) (10)
Chronic liraglutide therapy induces an enhanced endogenous glucagon‐like peptide‐1 secretory response in early type 2 diabetes (2017) (10)
Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus. (2013) (10)
Impact of Changes Over Time in Adipokines and Inflammatory Proteins on Changes in Insulin Sensitivity, β-Cell Function, and Glycemia in Women With Previous Gestational Dysglycemia (2017) (10)
Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study. (2012) (10)
HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy (2018) (10)
Community and International Nutrition A Pilot School-Based Healthy Eating and Physical Activity Intervention Improves Diet , Food Knowledge , and Self-Efficacy for Native Canadian Children 1 , 2 (2005) (10)
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10) (2019) (10)
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes (2014) (10)
Wavelength-modulated differential laser photothermal radiometry for blood glucose measurements (2010) (10)
Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies (2009) (9)
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? (2019) (9)
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? (2022) (9)
Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss (2009) (9)
Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine (2010) (9)
Diabetes: Steno-2 — a small study with a big heart (2016) (9)
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes (2022) (9)
Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes. (2000) (9)
Antepartum determinants of rapid early‐life weight gain in term infants born to women with and without gestational diabetes (2014) (8)
Applications of ultrasensitive wavelength‐modulated differential photothermal radiometry to noninvasive glucose detection in blood serum (2013) (8)
Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME (2018) (8)
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) (8)
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial (2020) (8)
Postpartum microalbuminuria after gestational diabetes: the impact of current glucose tolerance status. (2015) (8)
Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study (2010) (8)
Glucose control in type 1 diabetes: from conventional to intensive therapy. (1998) (8)
Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes (2002) (8)
Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. (2018) (8)
Effect of Empagliflozin On Cardiovascular Death in Subgroups Byage: Results From Empa-Reg Outcome (2016) (8)
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS (2020) (7)
The development of an artificial endocrine pancreas and its application in research and clinical investigation. (1977) (7)
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial (2021) (7)
Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial (2019) (7)
Factor V Leiden (F5 Q506) and Vascular Disease in Canadian Oji-Cree (1998) (7)
Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes : a systematic review and meta-analysis (2014) (7)
Traditional foods and 25(OH)D concentrations in a subarctic First Nations community (2016) (7)
The Effect of Direct Renin Inhibition on Renal Hemodynamic Function , Arterial Stiffness and Endothelial Function in Humans with Uncomplicated Type 1 Diabetes Mellitus : A Pilot Study (2009) (7)
Carotid Ultrasound in One, Two and Three Dimensions (2008) (7)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale and design (2018) (7)
Predictors and clinical implications of a false negative glucose challenge test in pregnancy. (2013) (7)
Biomarkers of tubulointerstitial damage and function in type 1 diabetes (2017) (7)
985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8 (2019) (7)
Rosiglitazone Associated Fractures in Type 2 Diabetes: An Analysis From ADOPT (2008) (7)
Non-invasive Glucose Measurements Using Wavelength Modulated Differential Photothermal Radiometry (WM-DPTR) (2012) (7)
Future options for insulin therapy (2002) (7)
Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes[S] (2018) (6)
Synergism between mutant HNF1A and the metabolic syndrome in Oji‐Cree Type 2 diabetes (2005) (6)
Changes over time in Uric Acid in relation to Changes in Insulin Sensitivity, Beta-cell Function, and Glycemia. (2019) (6)
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME (2021) (6)
Design of the Empagliflozin Cardiovascular (CV) Outcome Event Trial in Type 2 Diabetes (T2D) (2013) (6)
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. (2018) (6)
Glycemic Efficacy of Canagliflozin (CANA) is Largely Independent of Baseline Beta-Cell Function or Insulin Sensitivity (2014) (6)
Syndrome of Hypoglycemia Unawareness When Changing Insulin Species (1991) (6)
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial (2021) (6)
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME® (2020) (6)
Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes. (2019) (6)
Long term open loop intravenous insulin infusion in type I diabetes: feasibility, problems and promise. (1984) (6)
Glycaemic efficacy of canagliflozin is largely independent of baseline β‐cell function or insulin sensitivity (2016) (6)
EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL (2019) (6)
HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy (2018) (6)
Relationship Between Short Stature and Postchallenge Glycemia in Pregnancy (2010) (6)
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial (2020) (6)
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead. (2016) (6)
Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783 (2017) (6)
Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials (2018) (5)
The metabolic and hormonal responses to glucose infusion in anaesthetized normal and diabetic dogs controlled by an artificial B-cell (1980) (5)
Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12) (2020) (5)
Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (RESET‐IT Main): A 2‐year randomized controlled trial (2021) (5)
Diabetes: Progress in reducing vascular complications of diabetes (2014) (5)
Liraglutide and the Preservation of Pancreatic b-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014;37:3270-3278 (2015) (5)
Physical activity, fitness, and type I diabetes. (1994) (5)
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial (2021) (5)
Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction (2019) (5)
Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort (2021) (5)
Erratum: Adipokines and incident type 2 diabetes in a Canadian Aborigine population: The Sandy Lake Health and Diabetes Project (Diabetes Care (2008) 31 (1410-1415)) (2008) (5)
Insulin Regimens for Type 1 Diabetes (2003) (5)
The macrophage activation marker soluble CD163 is longitudinally associated with insulin sensitivity and β-cell function. (2020) (5)
Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk. (2015) (5)
EMPAGLIFLOZIN (EMPA) REDUCES MORTALITY IN ANALYSES ADJUSTED FOR CONTROL OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C OVER TIME (2017) (5)
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. (2021) (5)
Asymmetric dimethylarginine and arginine metabolites in women with and without a history of gestational diabetes. (2017) (4)
The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. (2019) (4)
How laboratory dogs accommodate meals of different size but similar composition. (1985) (4)
Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study (2018) (4)
Subtypes of gestational diabetes and future risk of pre-diabetes or diabetes (2021) (4)
Antihyperglycemic agents and cardiovascular outcomes: recent insights (2017) (4)
FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) (4)
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future (2021) (4)
Vitamin D status and cardiometabolic assessment in infancy (2013) (4)
Liraglutide Effects in Insulin-Treated Patients in LEADER (2018) (4)
Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy Short title: Glucagon after vildagliptin versus glimepiride (2010) (4)
Application of the Revised American Diabetes Association Criteria for the Diagnosis of Diabetes in a Canadian Native Population (1998) (4)
Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes (2012) (4)
Consistent effect of empagliflozin on cardiovascular death in subgroups by type of cardiovascular disease: results from EMPA-REG OUTCOME (2016) (4)
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. (2022) (4)
Type 2 diabetes mellitus: magnitude of the problem and failure to achieve glycemic control. (2006) (4)
Community and International Nutrition Specific Patterns of Food Consumption and Preparation Are Associated with Diabetes and Obesity in a Native Canadian Community 1 , 2 (1998) (4)
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy (2006) (4)
Glucoregulation in obese man: effects of fasting, glucagon infusion, exercise and diabetes. (1982) (4)
Response to Comment on: Goldberg et al. Circadian Variation in the Response to the Glucose Challenge Test in Pregnancy: Implications for Screening for Gestational Diabetes Mellitus. Diabetes Care 2012;35:1578–1584 (2013) (4)
Comparison of the clinical management of type 2 diabetes in Canada's First Nations peoples to national guidelines: the CIRCLE study (2009) (4)
Responses to mixed meals in pancreatectomized dogs deprived of postprandial insulin. (1982) (4)
Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299 (2020) (4)
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL (2020) (4)
Prospectively Planned Meta-Analysis comparing Hypoglycemia Rates of Insulin Degludec with those of Insulin Glargine (2012) (4)
Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial (2017) (4)
SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL (2018) (4)
The baseline metabolic state in bulimia nervosa : abnormality and adaptation (1992) (4)
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? (2022) (4)
Neighborhood walkability and risk of gestational diabetes (2020) (4)
FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) (4)
19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME (2019) (3)
Traditional foods and 25(OH)D concentrations in a subarctic First Nations community (2016) (3)
Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082 (2014) (3)
P2629Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial (2019) (3)
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes (2021) (3)
Changes in blood amino acids account for the insulin and glucagon responses to mixed meals in dogs. (1985) (3)
Circulating B‐type natriuretic peptide in women with and without recent gestational diabetes: The impact of current glucose intolerance (2018) (3)
Insulin dependent diabetes and the artificial pancreas. (1982) (3)
Exercise and diabetic control. (1977) (3)
Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life. (2022) (3)
Hemochromatosis and diabetes mellitus. (1998) (3)
Delivery by Caesarean section and infant cardiometabolic status at one year of age. (2014) (3)
Deintensification of Routine Medical Services The Next Frontier for Improving Care Quality (2017) (3)
Effect of short-term intensive insulin therapy on the incretin response in early type 2 diabetes. (2018) (3)
Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time (2017) (3)
The Effect of Insulin Degludec on Glycemic Control and Nocturnal Hypoglycemia Compared with Insulin Glargine: a 1-year Randomized Trial in Insulin-naïve People with Type 2 Diabetes (2012) (3)
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. (2022) (3)
Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (=65 Years) with Type 2 Diabetes (T2D)—Observations from DEVOTE (2018) (2)
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial (2022) (2)
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): A randomized, double-blind, placebo-control (2018) (2)
Controlled Crossover Study of Subcutaneous and Intravenous Insulin Infusion in Type I Diabetes (1987) (2)
Oscar B. Crofford: Clinician, Scientist, Educator, Advocate for People With Diabetes, and Godfather of Diabetes Control and Complications Trial (2014) (2)
Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c (2018) (2)
Diabetes research: are we getting anywhere? (1996) (2)
P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial (2018) (2)
RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES WITH AND WITHOUT PRIOR CARDIOVASCULAR EVENTS: RESULTS FROM THE LEADER TRIAL (2017) (2)
Exercise and insulin absorption. (1978) (2)
Differential impact of maternal and paternal ethnicity on the pattern of fat distribution in infants at age 3 months (2013) (2)
Beta-cell Function Declines within the First Year Postpartum in Women with Recent Glucose Intolerance in Pregnancy Running Title: Declining β-cell function in 1 st yr postpartum (2010) (2)
THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME (2019) (2)
Lifecourse: management of type 1 diabetes. (2014) (2)
Response to Wright and Little (1998) (2)
Baseline characteristics of participants enrolled in the empagliflozin cardiovascular outcome trial (EMPA-REG OUTCOME™) in patients with type 2 diabetes (2014) (2)
of Insulin Resistance in Infants at Age 1 Year Impact of gestational diabetes mellitus (2012) (2)
Intermittent Intensive Insulin Therapy for Type 2 Diabetes: Effects on Hypoglycemia, Weight Gain and Quality of Life Over 2 Years. (2019) (2)
Association between AGT codon 235 polymorphism and variation in serum concentrations of creatinine and urea in Canadian Oji‐Cree (1999) (2)
IDF World Diabetes Congress 2015 (2015) (2)
DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes (2020) (2)
SAT-305 EFFECTS OF EMPAGLIFLOZIN VS PLACEBO ON CARDIORENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOME (2019) (2)
Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9) (2019) (2)
Abstracts of the 49th Annual Meeting of the EASD (2013) (2)
Impact of liraglutide on reaching target HbA1c without weight gain or hypoglycaemia, versus other T2D therapies (2009) (2)
Preprogrammed Intravenous Insulin Infusion in Diabetic Humans: Metabolic Consequences of Altering Meal Size (1986) (2)
The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis. (2020) (2)
956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin (2020) (2)
Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride (2009) (2)
CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME (2017) (2)
Chapter 44 – Treatment of Type 1 Diabetes Mellitus in Adults (2016) (2)
Toxohormone in bacteria-free tumors. (1966) (2)
The clinical challenges of managing type 2 diabetes and the potential of GLP‐1‐based therapies (2009) (2)
SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) (2)
Abstract 15997: Empagliflozin Exerts Short- and Long-term Effects on Plasma Volume in Patients With Type 2 Diabetes: Insight From EMPA-REG OUTCOME (2017) (2)
Cardiovascular disease and the use of insulin. (2013) (2)
LBPS 02-49 IMPACT OF CHANGES IN GLUCOSE-LOWERING THERAPY ON ANALYSES OF GLYCEMIC CONTROL AND WEIGHT IN EMPA-REG OUTCOME (2016) (2)
Diabetes and exercise. (1979) (2)
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. (2023) (2)
Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". (2018) (1)
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes. (2022) (1)
THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2019) (1)
P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease (2019) (1)
Data sharing is desirable, but benefits should not be exaggerated (2015) (1)
Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain (2007) (1)
Serum urate and cardiovascular events in the DCCT/EDIC study (2021) (1)
Nocturnal confirmed hypoglycaemia with insulin degludec vs insulin glargine: rate ratios for different definitions (2015) (1)
SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS (2020) (1)
Factors affecting the urinary excretion of albumin in insulin-dependent diabetes. (1987) (1)
Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors? (2017) (1)
248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial (2022) (1)
ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS? (2017) (1)
Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial (2018) (1)
Glucose turnover in insulinoma--a case report. (1987) (1)
Optimal glycaemic control in unrestrained diabetic dogs using programmed compound squarewave insulin infusions (1981) (1)
Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes? (2016) (1)
Physical Health Status and Nocturnal Hypoglycemia with Insulin Degludec vs. Insulin Glargine: A 2-year Trial in Insulin-Naïve Patients with Type 2 Diabetes (2013) (1)
P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease (2019) (1)
Achieving fasting plasma glucose target without nocturnal hypoglycaemia: a pooled analysis of studies in type 2 diabetes comparing insulin degludec vs insulin glargine (2013) (1)
Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial (2019) (1)
Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448. (2022) (1)
Review: Intensive insulin therapy for type 1 diabetes mellitus increases risk for severe hypoglycemia, and pump therapy increases ketoacidosis (1998) (1)
Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis (2018) (1)
Emerging Strategies for the Management of Glycemic Control: The Role of Incretin Enhancers: Questions and Answers (2006) (1)
Peripheral insulinaemia and the glucoregulatory response to exercise in diabetic man. (1982) (1)
EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL (2016) (1)
Burden of type 2 diabetes-associated complications in Canada's First Nations peoples in 2007: the CIRCLE study (2009) (1)
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME (2019) (1)
ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes (2007) (1)
Improvements in Liver Enzymes with Empagliflozin in the EMPA-REG OUTCOME Trial (2018) (1)
Multiple Daily s.c. Insulin Doses (1980) (1)
QUALIFYING EVENT PROXIMITY, CARDIOVASCULAR RISK, AND BENEFIT OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND STABLE ATHEROSCLEROSIS IN THE EMPA-REG OUTCOME TRIAL (2019) (1)
Empagliflozin reduces mortality and hospitalisation for heart failure in patients with or without a history of myocardial infarction or stroke at baseline (2018) (1)
MS09.2 Empagliflozin Reduces Mortality In Patients With Type 2 Diabetes and A History of Left Ventricular Hypertrophy: A Sub-analysis of the EMPA-REG OUTCOME Trial (2018) (1)
LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME (2020) (1)
Abstract 14959: Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial (2020) (1)
PO121 RATE RATIOS FOR NOCTURNAL CONFIRMED HYPOGLYCAEMIA WITH INSULIN DEGLUDEC VS. INSULIN GLARGINE USING DIFFERENT DEFINITIONS (2014) (1)
Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER (2017) (1)
P3753Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial (2019) (1)
Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE (2018) (1)
Cardiovascular A 17 ( P 346 ) Severe hypoglycaemia , cardiovascular outcomes and death : Experience from the ‘ Liraglutide Effect and Action in Diabetes : Evaluation of Cardiovascular Outcome Results ’ ( LEADER ) trial (2018) (1)
PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL (2020) (1)
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome (2020) (1)
Hyponatremia from 1-Deamino-8-d-Arginine (dDAVP) Abuse (1980) (1)
28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME (2020) (1)
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES (2002) (1)
432-P: Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease (2019) (1)
129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial (2021) (1)
Pathological Significance of Pathological Significance of Glycemic Variability Glycemic Variability (2011) (1)
Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes (2010) (1)
Chapter 4 – The Biochemical Consequences of Hyperglycemia (2006) (1)
Efficacy and safety of inhaled insulin therapy. Authors' reply (2006) (1)
The pharmokinetics of insulin analogues and pumps (2001) (1)
Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial (2021) (1)
The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial. (2022) (1)
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME (2020) (1)
APPLICATION OF THE TIMI HEART FAILURE RISK SCORE TO THE EMPA-REG OUTCOME POPULATION (2020) (1)
Determination and kinetic analysis of non-insulin mediated glucose uptake in Type 1 (insulin-dependent) diabetes mellitus (2004) (1)
Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)-DEVOTE Results (2018) (1)
Screening glucose challenge test in pregnancy: impact of family history of diabetes on the likelihood of a false-negative result (2009) (0)
Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME (2020) (0)
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial (2020) (0)
Proinsulin and cardiovascular disease risk factors in a native Canadian population (2000) (0)
388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial (2019) (0)
ESICON 2018 Abstracts (2018) (0)
Heart Failure Outcomes in Patients with Diabetes With and Without Atrial Fibrillation – Data From the EMPA-REG OUTCOME Study (2019) (0)
Rosiglitazone plus metformin to prevent type 2 diabetes mellitus – Author's reply (2010) (0)
Common genetic variation in the APOC3 insulin response element is associated with elevated plasma triglycerides and apo B in aboriginal Canadians (1996) (0)
Abstract 13456: The Effect of Empagliflozin on Myocardial Extracellular Matrix Expansion in Patients With Type 2 Diabetes and Coronary Artery Disease (2019) (0)
Using Insulin Effectively in the Management of Diabetes (2004) (0)
EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME (2016) (0)
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME (2020) (0)
132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects (2020) (0)
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. (2023) (0)
Renal function following short-term insulin pump therapy in type i diabetes (1984) (0)
IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN 6 CLINICAL TRIALS (2019) (0)
Achieving FPG Target Without Hypoglycemia: A Meta-Analysis of Insulin Degludec vs. Insulin Glargine U100 (2016) (0)
EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK (2016) (0)
URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2019) (0)
P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial (2020) (0)
The heterogeneous response to exercise in diabetes mellitus. (1982) (0)
Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline (2018) (0)
Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial (2021) (0)
790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME (2021) (0)
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial (2022) (0)
Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial (2019) (0)
131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial (2021) (0)
Obstructive Sleep Apnoe and Cardiovascular, Heart Failure and Mortality Outcomes with Empagliflozin Versus Placebo in the EMPA-REG Outcome®Trial (2020) (0)
Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial (2020) (0)
Why sporadic glucose monitoring Why sporadic glucose monitoring when there is Continuous (CGM) (2014) (0)
27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (2020) (0)
Effect of empagliflozin when added to insulin in patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME trial (2017) (0)
Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin (2011) (0)
Erratum to “Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions” [Atherosclerosis 178(2) (2005) 319–325] (2005) (0)
ESICON 2019 Abstracts (2019) (0)
26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE (2020) (0)
Changes in bone metabolism biomarkers in the ADOPT study (2008) (0)
Vitamin D and Parathyroid Hormone Status in Pregnancy: Effect on Insulin Sensitivity, (cid:2) -cell Function, and Gestational Diabetes Mellitus (2014) (0)
Effect of rosiglitazone and ramipril on-cell function in people with impaired glucose tolerance ( IGT ) or impaired fasting glucose ( IFG ) : the DREAM Trial . Running title : Rosiglitazone , ramipril and-cell function (2009) (0)
248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial (2019) (0)
P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
Addition of liraglutide vs addition of a single dose of insulin aspart to insulin degludec plus metformin in patients with type 2 diabetes (2013) (0)
Obstetrical practices but not gestational metabolic abnormalities are associated with delayed onset of lactogenesis (2013) (0)
Abstract P069: Longitudinal Associations Between Metabolic Status, Insulin Clearance, and Insulin Sensitivity: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort (2019) (0)
Emerging Strategies for the Management of Glycemic Control: The Role of Incretin Enhancers (2006) (0)
HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY (2019) (0)
Can Combination Therapy Prevent Progression to Type 2 Diabetes (2011) (0)
Associations of total, bioavailable, and free 25(OH)D concentrations with insulin resistance and beta cell function in an Aboriginal Canadian community (628.5) (2014) (0)
Abstract 14961: External Applicability of REDUCE-IT in a Large Diabetes Cardiovascular Outcomes Trial: A Post Hoc Analysis of EMPA-REG OUTCOME (2020) (0)
Cardiovascular Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (≥65 Years) with Type 2 Diabetes: Observations From DEVOTE (2018) (0)
Circulating Vitamin DMetabolites and Subclinical Atherosclerosis in Type 1 Diabetes (2013) (0)
ESICON 2017 Abstracts (2017) (0)
P1876Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial (2018) (0)
Empagliflozin Reduces Mortality in Patients with Type 2 Diabetes and a History of Left Ventricular Hypertrophy: A Sub-Analysis of the EMPA-REG OUTCOME Trial (2018) (0)
099-S: Lifestyle Variables, Non-Traditional Cardiovascular Risk Factors and the Metabolic Syndrome in an Aboriginal Canadian Population (2005) (0)
Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". (2017) (0)
Health Sciences Research Commons (2014) (0)
Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME (2020) (0)
Abstract #289 Effect of Linagliptin on Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes and Kidney Disease: Carmelina® (2019) (0)
P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial (2019) (0)
Achieving FPG Target Without Nocturnal Hypoglycemia: A Pooled Analysis of Studies in Type 2 Diabetes Comparing Insulin Degludec vs. Insulin Glargine (2013) (0)
Impact of maternal prenatal metabolic abnormalities on metabolic hormones in human milk (2012) (0)
7.2 Physical Health Status and Nocturnal Hypoglycemia with Insulin Degludec vs. Insulin Glargine: A 2-Year Trial in Insulin-Naïve Patients with Type 2 Diabetes (934-P) (2013) (0)
Review: Intensive blood-glucose control reduces diabetic complications in patients with insulin-dependent diabetes mellitus (1993) (0)
Dietary fat and carbohydrate intake during early pregnancy and risk of gestational diabetes (2011) (0)
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (2021) (0)
OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience (2019) (0)
Finite Element Calculation of Microwave Absorption by the Cranial Structure (1980) (0)
Efficacy of Semaglutide by Background Sodium–Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9 (2019) (0)
Exercise and diabetes (1981) (0)
Author response for "Long‐term efficacy and safety of combined insulin and GLP‐1 therapy: evidence from the LEADER trial" (2019) (0)
Efficacy and Safety of Inhaled Insulin Therapy (2006) (0)
A portable device for the subcutaneous injection of a liquid medication (1981) (0)
Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial (2021) (0)
Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME (2020) (0)
PO415 GREATER PPG CONTROL ACROSS ALL 3 MAIN MEALS WITH LIRAGLUTIDE VS PLACEBO, WHEN ADDED ON TO METFORMIN AND ROSIGLITAZONE (2014) (0)
Increased incidence of fractures in women who received rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial) (2007) (0)
Author response for "The Ongoing Evolution of Basal Insulin Therapy over 100 Years and its Promise for the Future" (2021) (0)
RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis (2022) (0)
The metabolic and hormonal responses to a mixed meal in umestrained pancreatectomised dogs chronically treated by portal or peripheral insulin infusion (1981) (0)
Non-invasive Glucose Measurements Using Wavelength Modulated Differential Photothermal Radiometry (WM-DPTR) (2012) (0)
952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial (2020) (0)
P2-25 Effects of intrauterine glycemia on infant weight gain over the first 3 months of life (2007) (0)
Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076–1082 (2014) (0)
Response to Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic β-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014;37:3270–3278 (2015) (0)
Canadian Foundation for Dietetic Research Showcase of Dietetic Research in Canada – June 12-14, 2008 (2008) (0)
Risk of Major Cardiovascular Events in Patients With Type 2 Diabetes With and Without Prior CV Events: Results From The LEADER Trial (2018) (0)
Correction to: The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement (2021) (0)
Continuous Intravenous Insulin Infusion in Ambulatory Type I Diabetics: Effect of Diet on Insulin Requirements (1987) (0)
[Effect of glycemic equilibrium on micro-angiopathic complications in insulin-dependent diabetes: results of recent studies]. (1994) (0)
Continuous subcutaneous insulin infusion versus multiple daily injections : The impact of baseline A1c. Author's reply (2005) (0)
Diabetes Education for Adults Diabetes Education for Adults with Diabetes (Part 2) with Diabetes (Part 2) (2013) (0)
EFFECTS OF EMPAGLIFLOZIN ON DIASTOLIC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2019) (0)
Consensus Reports (2011) (0)
1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial (2020) (0)
Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy. (2023) (0)
P21 Effect of insulin degludec vs insulin glargine in a one-year randomized trial in insulin-naïve patients with type 2 diabetes (2013) (0)
P2858Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial (2018) (0)
Heart failure and diabetes: a treacherous combination 1023 HEART FAILURE AND DIABETES: A TREACHEROUS COMBINATION 4879 | BEDSIDE Heart failure with mid range ejection fraction, characteristics and prognosis in patients with and without type 2 diabetes (0)
Multiple insulin injection therapy delayed microvascular complications in NIDDM (1996) (0)
Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis (2018) (0)
Response to the Letter by Kalra S. et al. (2015) (0)
Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial (2020) (0)
SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA (2019) (0)
Meta-Analysis Comparing Hypoglycemia Rates of Insulin Degludec with Insulin Glargine U100 Across Clinical Trials with up to 2 Years' Duration (2016) (0)
The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes (2023) (0)
GLYCEMIC RECOVERY IN IV INFUSED DIABETICS RECEIVING MEALS OF DIFFERENT SIZES (1984) (0)
Lower hypoglycemia rates with insulin degludec compared to insulin glargine: Data from a prospectively planned meta-analysis (2013) (0)
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. (2022) (0)
249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status (2022) (0)
Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME (2021) (0)
Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME (2021) (0)
[Physiopathology of diabetes and the artificial endocrine pancreas]. (1976) (0)
Minutes of the 21st General Assembly of the European Association for the Study of Diabetes (2004) (0)
Author response for "The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial" (2021) (0)
P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline (2018) (0)
Determinants of monotherapy failure in ADOPT - (A diabetes outcome progression trial) (2007) (0)
Human ehrlichiosis in Thailand (1997) (0)
Excessive Glycaemic Variability Excessive Glycaemic Variability as an Indication for CSII as an Indication for CSII (2008) (0)
Diabetes Mellitus and Exercise (1984) (0)
Is brittle diabetes an Is brittle diabetes an indication for alternative indication for alternative methods of insulin delivery? methods of insulin delivery? (2007) (0)
GSK’s ROSIGLITAZONE MALEATE (AVANDIA) REDUCES RISK OF PROGRESSION FROM PRE-DIABETES TO TYPE 2 DIABETES BY 62 PERCENT IN LARGEST-EVER DIABETES PREVENTION TRIAL Pre-diabetes Estimated to Affect 300 Million People Globally (2007) (0)
926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial (2020) (0)
LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL (2018) (0)
The HNF1A G319S variant is associated with C-reactive protein in an Aboriginal population (2009) (0)
Bioelectrical Impedance Analysis (BIA) Using Bipolar Foot Electrodes in the Assessment of Body Composition in Type 2 Diabetes Mellitus BIOIMPEDANCE VALIDATION - Type 2 Diabetes Mellitus (1998) (0)
Public Policy Toward the Development and Evaluation of Devices for the Control of Diabetes Mellitus (1979) (0)
SP415 EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOMER TRIAL (2018) (0)
IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS (2019) (0)
Insulin led to lower glucose levels, less combination therapy, and more weight gain in type 2 diabetes mellitus (1998) (0)
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial (2020) (0)
Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus? (2008) (0)
Late‐breaking Trials (2006) (0)
Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The Impact of Baseline A1c: Response to Blumer (2005) (0)
721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8 (2022) (0)
[Risk factors in proliferating diabetic retinopathy]. (1982) (0)
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial (2021) (0)
An optimist's view of the future (1996) (0)
133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE (2021) (0)
THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME (2020) (0)
patient-oriented and epidemiological research Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes (2009) (0)
LBPS 02-47 CARDIOVASCULAR OUTCOMES ACCORDING TO LDL CHOLESTEROL LEVELS IN EMPA-REG OUTCOME (2016) (0)
1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial (2020) (0)
Personal Considerations on Personal Considerations on Clinical Development of Clinical Development of Continuous Glucose Continuous Glucose Monitoring Systems Monitoring Systems (2007) (0)
1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (2020) (0)
Efﬁcacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With T ype 2 Diabetes (LEAD-4 Met (cid:1) TZD) (2010) (0)
162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial (2020) (0)
Examining the relationship between maternal body size, gestational glucose tolerance status, mode of delivery and ethnicity on human milk microbiota at three months post-partum (2020) (0)
THE PRESENT AND FUTURE STATE-OFTHE - (0)
Association of parity with risk of diabetes and related disorders in a native Canadian population (2000) (0)
’ s response to reviews Title : Rationale and design of the CAROLINA ®-cognition substudy : a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus (2018) (0)
Factor V Leiden (F5 Q506) and Vascular Disease in (1998) (0)
After Metformin, What Comes Next? Empagliflozin? (2015) (0)
The authors reply. (2020) (0)
Private drug coverage is not associated with better attainment of glycaemic targets in a Canadian glycaemic treatment optimization program (2009) (0)
Time to do more: Feedback based national glycaemic treatment optimization program can improve attainment of glycaemic targets (2009) (0)
The Use of the Continuous The Use of the Continuous Glucose Monitors in Glucose Monitors in Pr Pr egnancy egnancy (2007) (0)
Degludec insulin, insuline ultra long of new generation, used once a day or 3 times per week in patients with type 2 diabetes: comparison with insulin Glargine (2011) (0)
A NOVEL ROLE OF SGLT2 INHIBITORS TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE: A SUB-STUDY OF THE EMPA-HEART CARDIOLINK-6 TRIAL (2019) (0)
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes. (2023) (0)

This paper list is powered by the following services:

Other Resources About Bernard Zinman

en.wikipedia.org

What Schools Are Affiliated With Bernard Zinman?

Bernard Zinman is affiliated with the following schools:

Bernard Zinman's Academic­Influence.com Rankings

Why Is Bernard Zinman Influential?

Bernard Zinman's Published Works

Published Works

Other Resources About Bernard Zinman

What Schools Are Affiliated With Bernard Zinman?

Bernard Zinman's AcademicInfluence.com Rankings